ZA200110044B - Use of dopamine D receptor ligands for producing medicaments for treating kidney disorders. - Google Patents

Use of dopamine D receptor ligands for producing medicaments for treating kidney disorders.

Info

Publication number
ZA200110044B
ZA200110044B ZA200110044A ZA200110044A ZA200110044B ZA 200110044 B ZA200110044 B ZA 200110044B ZA 200110044 A ZA200110044 A ZA 200110044A ZA 200110044 A ZA200110044 A ZA 200110044A ZA 200110044 B ZA200110044 B ZA 200110044B
Authority
ZA
South Africa
Prior art keywords
dopamine
receptor ligands
treating kidney
kidney disorders
producing medicaments
Prior art date
Application number
ZA200110044A
Other languages
English (en)
Inventor
Muehlbauer Bernd
Gerhard Gross
Dorothea Starck
Hans-Joerg Treiber
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA200110044B publication Critical patent/ZA200110044B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
ZA200110044A 1999-05-07 2001-12-06 Use of dopamine D receptor ligands for producing medicaments for treating kidney disorders. ZA200110044B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19922443A DE19922443A1 (de) 1999-05-07 1999-05-07 Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen

Publications (1)

Publication Number Publication Date
ZA200110044B true ZA200110044B (en) 2003-03-06

Family

ID=7908194

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200110044A ZA200110044B (en) 1999-05-07 2001-12-06 Use of dopamine D receptor ligands for producing medicaments for treating kidney disorders.

Country Status (19)

Country Link
US (2) US7098214B1 (no)
EP (1) EP1176963B1 (no)
JP (3) JP4727822B2 (no)
KR (2) KR20010112474A (no)
CN (2) CN101524356A (no)
AT (1) ATE284693T1 (no)
AU (1) AU770671B2 (no)
BR (1) BR0010337A (no)
CA (1) CA2368823C (no)
CZ (1) CZ301832B6 (no)
DE (2) DE19922443A1 (no)
DK (1) DK1176963T3 (no)
ES (1) ES2234597T3 (no)
HU (1) HU228516B1 (no)
IL (2) IL146232A0 (no)
NO (1) NO329325B1 (no)
PT (1) PT1176963E (no)
WO (1) WO2000067847A2 (no)
ZA (1) ZA200110044B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
WO2001024796A1 (en) * 1999-10-01 2001-04-12 Smithkline Beecham Corporation 1,2,4-triazole derivatives, composition, process of making and methods of use
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
IL157413A0 (en) 2001-02-16 2004-03-28 Aventis Pharmaceuticals Inc Av Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
WO2002066468A2 (en) * 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
EP1361875A2 (en) * 2001-02-16 2003-11-19 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109867A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
EP1381360A4 (en) * 2001-03-29 2009-12-02 Smithkline Beecham Corp COMPOUNDS AND METHODS FOR INHIBITING METAP2 IN MAMMALS
DE10131543A1 (de) * 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
WO2003065871A2 (en) * 2002-02-04 2003-08-14 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
ATE397755T1 (de) * 2003-03-17 2008-06-15 Bayer Healthcare Ag Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
ES2340941T3 (es) * 2004-08-09 2010-06-11 ABBOTT GMBH & CO. KG Compuestos de 4-piperazinil-pirimidina adecuados para tretar trastornos que responden a modulacion del receptor d 3 de dopamina.
KR101315192B1 (ko) 2004-10-14 2013-10-10 애보트 게엠베하 운트 콤파니 카게 도파민 ｄ3 수용체 조절에 반응하는 질환 치료에 적합한헤테로사이클릭 화합물
NZ589649A (en) 2004-10-14 2012-04-27 Abbott Gmbh & Co Kg Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
WO2006040179A1 (en) 2004-10-14 2006-04-20 Abbott Gmbh & Co. Kg Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
WO2006040177A1 (en) 2004-10-14 2006-04-20 Abbott Gmbh & Co.Kg 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 recptor
WO2007120528A2 (en) * 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
WO2008016171A1 (fr) * 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Agent prophylactique/thérapeutique destiné à un dysfonctionnement rénal
US20110028491A1 (en) * 2008-01-25 2011-02-03 Nihon University Apoptosis inhibitor
KR20190028281A (ko) 2017-09-08 2019-03-18 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE628766A (no) * 1962-12-26
US3290004A (en) * 1965-04-09 1966-12-06 Hitachi Ltd Device for damping vibration of long steam-turbine blades
DE4223921A1 (de) 1992-07-21 1994-01-27 Hartmut Prof Dr Med Oswald Herstellung und Verwendung von Hemmstoffen der DOPA-Decarboxylase sowie von Dopamin-Rezeptor-Antagonisten zur Bekämpfung der fortschreitenden Verschlechterung der Nierenfunktion beim Menschen
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen

Also Published As

Publication number Publication date
WO2000067847A3 (de) 2001-08-02
ES2234597T3 (es) 2005-07-01
AU770671B2 (en) 2004-02-26
HU228516B1 (en) 2013-03-28
IL146232A0 (en) 2002-07-25
NO20015413D0 (no) 2001-11-06
KR20010112474A (ko) 2001-12-20
JP5542713B2 (ja) 2014-07-09
CA2368823C (en) 2008-10-21
CN1360502B (zh) 2010-08-04
ATE284693T1 (de) 2005-01-15
US8785447B2 (en) 2014-07-22
EP1176963B1 (de) 2004-12-15
EP1176963A2 (de) 2002-02-06
AU4559100A (en) 2000-11-21
KR20070040425A (ko) 2007-04-16
NO20015413L (no) 2001-11-15
BR0010337A (pt) 2002-02-13
CA2368823A1 (en) 2000-11-16
HUP0202399A3 (en) 2003-02-28
DE50008964D1 (de) 2005-01-20
JP2011088941A (ja) 2011-05-06
US7098214B1 (en) 2006-08-29
US20060223793A1 (en) 2006-10-05
NO329325B1 (no) 2010-09-27
KR100781828B1 (ko) 2007-12-03
CZ20014015A3 (cs) 2002-02-13
PT1176963E (pt) 2005-05-31
HUP0202399A2 (hu) 2002-12-28
CN101524356A (zh) 2009-09-09
DE19922443A1 (de) 2000-11-09
JP2002544178A (ja) 2002-12-24
JP2014098044A (ja) 2014-05-29
WO2000067847A2 (de) 2000-11-16
CN1360502A (zh) 2002-07-24
IL146232A (en) 2007-06-03
JP4727822B2 (ja) 2011-07-20
CZ301832B6 (cs) 2010-07-07
JP5897054B2 (ja) 2016-03-30
DK1176963T3 (da) 2005-04-25

Similar Documents

Publication Publication Date Title
ZA200110044B (en) Use of dopamine D receptor ligands for producing medicaments for treating kidney disorders.
BG108495A (en) 5-ht receptor ligands and uses thereof
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
IL190654A (en) Methods of Methyl-Sulfonamido-Propanamido, Processes for Preparation and Medicines Containing Them
WO1999017755A3 (en) Medicaments
HK1044769A1 (en) Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof.
IL210046A0 (en) Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
EP1149078A4 (en) 5-HT 6 RECEPTOR LIGANDS? SELECTIVE
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
GB9716879D0 (en) Treatment of attention deficit disorders
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
WO2003037863A3 (de) Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung
WO2001049654A3 (de) Substituierte aminomethyl-phenyl-cyclohexanderivate
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
AU2002358469A1 (en) Modified receptors for the discovery of therapeutic ligands
CY2456B1 (en) At1 receptor antagonist for the stimulation of apoptosis.
WO2004022542A3 (de) Substituierte 1,2,3,4-tetrahydrochinolinderivate
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
MXPA04001205A (es) Compuesto para eliminar y/o mitigar la anhedonia.
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
WO2003059352A3 (fr) Utilisation d'une nouvelle classe de medicaments pour le traitement de maladies parasitaires
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей